This new volume focuses on the bioimaging of Parkinson's, Alzheimer's, and the epilepsies, presenting the latest in the technologies that diagnose and treat the person who has the disease, enabling personalized medicine. The book presents chapters on the "know-how" of the technologies, the nanotechnologies and functional nuclear and molecular imaging of neurodegenerative early and late-stage biomarkers. Technology has evolved in conceptual, theoretical and empirical leaps and bounds. A metallopolymer of the tau peptide is imaged online in PD subjects with nanoprobe biosensors, trademarked BRODERICK PROBE® via neuromolecular imaging (NMI), a non-nuclear potentiometry that enables algorithms for walking and hand mobility patterns and hypokinetic dysarthria in PD patients is detected using Conventional Neural Networks (CNN). Magnetic resonance imaging (MRI) and dopamine transporter single-photon emission computed tomography (DAT-SPECT) in degenerative parkinsonism and related disorders differentially diagnose PD from essential tremor, (ET), parkinsonian syndrome, (PS) and dystonia tremor (DT) and atypical parkinsonian syndromes including multiple system atrophy (MSA) and progressive supranuclear palsy (PSP) are also differentiated from Atypical PD. Approaches to imaging both pre- and post-synaptic function highlight molecular nuclear imaging via 18F-DOPA PET/SPECT imaging in PD and intraoperative images of neocortical Tau in the epilepsy patient are recorded with NMI guided by iMRI by Broderick nanoprobes. Subclinical Epileptiform Activity (SAE) of the AD patient is introduced as a likely phenotype for epilepsy in the AD patient whereas a stimulation paradigm, used in the brainstem of diabetic subjects, links to degenerative neuropathy. The profundity of epilepsy disorders such as in status epilepticus (SE) are reported as Increased T2 or fluid-attenuated inversion recovery (FLAIR) in MRI. Childhood tuber and focal cortical dysplasia are shown by high AMT uptake on PET imaging, introducing the PET tracer alpha[11C]-methyl-L-tryptophan (AMT) to intractable epileptogenesis while proton magnetic resonance spectrometry (MRS) delves into the Alzheimer patient to image N-acetyl aspartate for one example. Finally, natural cannabis compounds (CBD), as their biochemistry relate to Aß peptide via the Wnt/ß-catenin and other intriguing signalling pathways, are discussed in-depth. The book is a textbook for those who seek advice about tracer probes and sensor probes for the dementia diseases related to AD. The reader shall find the book, all encompassing and hopefully, it shall embrace all to the vitality of the issue of neurodegeneration in the human and the humanoid.
Reihe
Sprache
Verlagsort
Verlagsgruppe
Springer International Publishing
Illustrationen
55
26 s/w Abbildungen, 55 farbige Abbildungen
X, 281 p. 81 illus., 55 illus. in color.
ISBN-13
978-3-031-95878-6 (9783031958786)
Schweitzer Klassifikation
Dr. Patricia A. Broderick, PhD is a Full, Medical Professor with Tenure at the City University of New York Medical School, Dept. of Molecular, Cellular and Biomedical Science, USA where she also holds faculty positions at the CUNY Grad Ctr.: Psychology: Cognitive and Behavioral Neuroscience as well as at CUNY Neuroscience Collaborative Graduate Program: Biology. Patricia served as the Director of Pharmacology at the City University of New York Physician Assistant/MS program at the CUNY Medical School and Director of the Neurobiology of Drugs of Abuse Course as well as Adjunct Professor in Neurology and the Comprehensive Epilepsy Center at NYU Langone Medical Center, USA. As graduate, doctoral, medical, physician assistant and high school mentor, her innovative teaching is deeply appreciated. As principal and founder of Eazysense Nanotechnologies Inc., the Broderick Brain Foundation Inc. and inventor of the BRODERICK PROBE® series of nanobiosensors and circuits, Patricia has garnered respect and admiration worldwide. Achieving her PhD in Pharmacology from St. John's University, College of Arts and Sciences, NY, USA, her expertise in the field of atomic absorption photometry and fluorescent spectrometry, her inventive neuroimaging art in the biosensing and bioimaging field at the Albert Einstein College of Medicine and Cornell University, NY, USA, makes sense. Indeed, as postdoctoral fellow, Dr. Broderick was awarded the Rosenbaum Award from Albert Einstein Medical School/Montefiore Hospital and her patents began at the Albert Einstein College of Medicine are now held by CUNY. Patricia has published and patented extensively and has garnered respect for her novel research around the world. The BRODERICK PROBE® trademark, named after her father, brings a solid brand as the nanoprobe is poised for marketing her unique cutting-edge nanotechnology in the field of Neuroscience. She is the recipient of multiple grants awards and prestigious honors from organizations such as Inner Circle Executives, Acquisitions International Global/Corporate America, International Association of Professionals, National Association of Distinguished Professionals and Top Industry Experts from Patient Preferred Physicians and Practitioners was celebrated in 2024. A pivotal figure in biosensing technology and the brain, spinal cord and the skin, Broderick served as Session Chair, at the Virtual International Electronic Conference on Brain Sciences, Beijing, October, 2024 and her pending 2025 patent application for replenishing skin as well as her multiple patents are recognized by major diagnostic and pharmaceutical markets, worldwide. Prof. Broderick serves on the editorial boards of several prestigious scientific and medical journals and her work as editor, author and lecturer is renowned. No stranger to the airways, Patricia is a sought-after speaker and her weekly talk show, The Eazysense Show, is at the top of the list at Bold Brave Media (BBM) Productions. Patricia's unwavering dedication to advancing the understanding of neurological, psychological and mental health is reflected in her latest launched textbook, Broderick PA (2025) NEUROIMAGING: Sensing Biochemistry in the Brain, Jenny Stanford Publishing, Pte Ltd., Singapore.The Editor thanks Springe Nature for the opportunity to lead the most talented and influential physicians and scientists in the world via this book, Biomedical Imaging in Neurodegeneration.
Magnetic Resonance Imaging and Magnetic Resonance Spectroscopy in Parkinson's Disease.- Positron Emission Tomography and Single-Photon Emission Tomography in the Diagnosis of Parkinson's Disease.- Positron Emission Tomography in Parkinson's Disease.- [123I]-Altropane SPECT.- Positron Emission Tomography and Embryonic Dopamine Cell Transplantation in Parkinson's Disease.- Neurotoxicity of the Alzheimer's Amyloid Peptide.- Functional Imaging and Psychopathological Consequences of Inflammation in Alzheimer's Dementia.- Neurotoxic Oxidative Metabolite of Serotonin.- Predicting Progression of Alzheimer's Disease With Magnetic Resonance.- Stages of Brain Functional Failure in Alzheimer's Disease.- Epilepsy.- Neocortical Epilepsy.- Pediatric Cortical Dysplasia.- Bioimaging L-Tryptophan in Human Hippocampus and Neocortex.- In Vivo Intrinsic Optical Signal Imaging of Neocortical Epilepsy.- Intraoperative Magnetic Resonance Imaging in the Surgical Treatment of Epilepsy.- Periodic Epileptiform Discharges Associated With Increased Cerebral Blood Flow.- Imaging White Matter Signals in Epilepsy Patients.- - Overview of the Leukoencephalopathies.- Pyramidal Tract Involvement in Adult Krabbe's Disease.- Imaging Leukodystrophies.- Advanced Magnetic Resonance Imaging in Leukodystrophies.- Childhood Mitochondrial Disorders and Other Inborn Errors of Metabolism Presenting With White Matter Disease.- Mitochondrial Disease.
